排泄ABCC1/MRP1构成性地限制了癌细胞中的PROTAC敏感性
Gernot Wolf1, Conner Craigon2, Shao Thing Teoh1
1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
Cell chemical biology
|January 4, 2025
概括
细胞转运器限制了蛋白质分解向化母 (PROTAC) 的有效性. 研究人员确定ABCC1/MRP1是PROTAC抗性的关键因素,对于克服癌症治疗中药物限制至关重要.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化向化体 (PROTACs) 是双功能分子,可实现向蛋白质降解.
- 在临床试验中,PROTACs有潜力向以前无法药物治疗的蛋白质,有几个候选人.
- 细胞载体在PROTAC药理动力学中的作用在很大程度上是未知的.
研究的目的:
- 研究细胞跨膜载体在PROTAC吸收和流出中的作用.
- 确定导致PROTAC耐药性的遗传因素.
主要方法:
- 利用转运器专注的遗传选来识别PROTAC耐药性因素.
- 进行了全基因组的PROTAC耐药性选.
主要成果:
- 确定了ATP结合盒载体ABCC1/MRP1作为一个重要的PROTAC抗性因子.
- 在各种癌症中,ABCC1的构成性表达,限制了PROTAC的生物可用性.
- 确定了在PROTAC耐药性中涉及的无处不在,mTOR信号和亡途径.
结论:
- 在癌细胞中,ABCC1充当关键的排泄,限制了PROTAC在癌细胞中的有效性.
- 研究结果提供了关于克服PROTAC耐药性的见解,以改善癌症治疗.
关键词:
ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1ABCC1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1C1这就是CRISPR/Cas9的作用.在MRP1中,MRP1是MRP1.这就是 PROTACs.毒品运输是毒品的运输方式.基因查 基因查 基因查溶解物载体 (SLC) 是一种载体.相关概念视频
Carrier-Mediated Transport
247
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
247
ABC Transporters: Exporter
4.1K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.1K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
ABC Transporters: Importer
2.7K
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
2.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


